While inhibition of MDM2 has widely been shown to be an effective therapeutic approach in p53 wild-type tumors [13,26], little is known about its role in cancers harboring inactivating p53 mutations, including TNBC, especially when tested not only in combination but also as a monotherapy. This evidence concerns the gene TP53 and cancer.